# A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT05866692** · PHASE1 · RECRUITING · sponsor: **TYK Medicines, Inc** · enrollment: 156 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** TY-2699a

## Key facts

- **NCT ID:** NCT05866692
- **Lead sponsor:** TYK Medicines, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-17
- **Primary completion:** 2025-10
- **Final completion:** 2026-10
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05866692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05866692, "A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05866692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*